GSK3A and endometrial cancer: Consistently, data from Human Protein Atlas showed that liver cancer and endometrial cancer patients with higher levels of GSK3α expression exhibited worse overall survival times than their low-expression counterparts (Additional file 2: Fig. S1d–e).